Osteoblastoma vs Osteosarcoma

  • Nour Asaad MSc Applied Biomolecular Technology, BSc Biochemistry and Molecular Medicine, The University of Nottingham
  • Zayan Siddiqui BSc in Chemistry with Biomedicine, KCL, MSc in Drug Discovery and Pharma Management, UCL

Get health & wellness advice into your inbox

Your privacy is important to us. Any information you provide to us via this website may be placed by us on servers. If you do not agree to these placements, please do not provide the information.

Best Milk Alternative

Overview

Have you got a passion for bones and their pathologies? Do you want to learn more about bone tumours and their types? In this article, we will be covering two interesting diseases: osteoblastoma and osteosarcoma. So, what are they? Both are tumours of the bone however, one is benign while the other is malignant and they usually occur in young adults/teens.1, 2 To better understand the differences between the two, this article will provide a comparison between the two illnesses. So let us dive in.

Osteoblastoma

Definition and characteristics

As mentioned in the introduction, osteoblastoma is a type of bone tumour.1 It is defined by marked new bone production/formation with vascularised lesions.3 The production seen in osteoblastoma tends to be in the form of trabecular bone that lacks organisation, a low abundance of nerve fibres, and prostaglandins.3 Malignant transformation and metastatic diseases have been reported and associated with osteoblastoma.3

Epidemiology

Osteoblastoma is the most common benign primary bone tumour and predominantly affects children aged between 10 to 15 years and young adults (20 years old) and is more common in people assigned male at birth than people assigned female at birth.1, 3 It is also known for its osteoblastic (bone formation) nature and local aggression, which is slightly more common in older patients (33 years old).1 Throughout different studies, it was concluded that osteoblastoma makes up 1 to 5% of all benign tumours and 1% of all bone-related tumours.1, 4  

It is commonly present in the spine and sacrum (around 28-55% of cases) involving the posterior elements of the spine however, it can also be present in other areas such as the femurs (12%), the jaw (11%), the tibia (10%), and the feet and ankles (9%).3, 4

Signs and symptoms

Signs and symptoms in osteoblastoma can sometimes be hard to see; at times, osteoblastoma presents itself as an asymptomatic, or slow-growing tumour and is picked up when performing tests for other causes and reasons such as aneurysmal bone cyst.4, 5 However, in the case of a symptomatic osteoblastoma, the common symptoms include swelling and localised pain that is not responsive to pain relievers or NSAIDs, along with the presence of fever and weight loss.4

When referring to osteoblastoma on a histological scale, it is a benign bone-forming tumour which is similar to osteoid osteoma (which is a tumour that has no potential to be malignant). In fact, it used to be referred to as a giant osteoid osteoma due to the similarities between the two.1, 3 Although both of these cases are derived from the same osteoblastic lesional process, osteoblastoma is typically more aggressive clinically and radiologically.1

In 1984, Dorfman and Weiss introduced a new term called ‘aggressive osteoblastoma’ which is a borderline osteoblastic tumour entity; it was associated with a high recurrence rate and potential for malignant development and transformation.1 Even though osteoblastomas are benign tumours, they can cause significant bone destruction, soft tissue infiltration and epidural extension.1 

If left untreated, the distal aggressiveness of the tumour can lead to malignant transformation and the destruction of the spine, with a high risk of neurological deficits in severe cases.1

Causes

Currently, it is not known what causes osteoblastoma and what the risk factors are for this case.3, 5

Testing and diagnosis

Testing for  osteoblastoma can be done in various ways:5

  • X-rays: To see the images of the bones
  • Magnetic resonance imaging (MRI): Incorporates the use of large magnets, radio frequencies, and a computer to give detailed images of organs, soft tissues, muscles, ligaments, and other structures inside the body.
  • Computed tomography (CT) scan: This involves the use of X-rays and computer technology to produce cross-sectional images, known as "slices", of the body.
  • EOS imaging: An imaging technology that creates 3-D models from 2 planar images. Unlike a CT scan, EOS images are taken while the patient is in an upright/standing position, which enables improved diagnosis due to weight-bearing positioning.
  • Needle biopsy: This involves the use of a small needle that is inserted through the skin and into the lesion to withdraw a small sample of the aberrant tissue. The tissue is later analysed to confirm any findings.

Osteosarcoma

Definition and characteristics

Osteosarcoma is the most common type of bone cancer that occurs in children and adolescents and 3rd most common in adults.2, 6 It is derived from bone-forming mesenchymal cells.2 It can occur in 2 forms: the first one has no underlying bone pathology and the second with underlying pathology that had malignant degeneration or conversion occur.7 Osteosarcoma represents itself as highly heterogeneous and this leads to several subtypes being differentiated based on the degree of tumour differentiation, location in the bones and histological variations.7

Epidemiology

Osteosarcoma has a bimodal age distribution; the initial peak is in patients aged 10-14 which is linked to a pubertal growth spurt, while the next observable peak is in adults (>65 years old) where the malignancy is secondary to other diseases such as malignant degeneration of Paget disease, bone infarction and others.7

There are other factors such as race and sex that play a role in osteosarcoma; Black people are the ethnic group that predominantly face osteosarcoma, followed closely by Hispanics and white people respectively.7 Additionally, males assigned at birth have higher incidences than females assigned at birth.7

Osteosarcoma commonly occurs close to the metaphysis of the long bones of the appendicular skeleton.7 The most common locations are:7

  • Femur: 42%, with 75% of tumours in the distal portion of the bone
  • Tibia: 19%, with 80% of tumours in the proximal portion of the bone
  • Humerus:10%, with 90% of tumours in the proximal portion of the bone
  • Other potential sites include the skull/jaw (8%) and the pelvis (8%)

As mentioned before, osteosarcoma can be categorised into primary and secondary forms:7

  • Primary tumours: usually occur in the metaphysis of long bones (mostly in the knees); around 60% occur in this area. These tumours occur mostly in children and adolescents.
  • Secondary tumours: have a much wider distribution which is linked to the varied nature of their underlying predisposing condition. It is more common in flat bones, particularly the pelvis, and is almost always in the adult population. 

Signs and symptoms

Symptoms associated with osteosarcoma can be present for a long time (weeks/months) before the patient goes for a diagnosis.7 The most common symptoms include bone pain, especially during activity.7 Other symptoms include:7, 8

  • Swelling around the affected site
  • Limping
  • Decreased movement of the affected limb
  • Fever and night sweats
  • Local or regional lymphadenopathy (uncommon)
  • Respiratory findings with metastatic forms (rare)

Causes

The cause of osteosarcoma remains unclear however, there have been studies regarding the roles of genetics, epidemiology and environment.7 Some of these genetic alterations in cases of primary osteosarcoma include:7,

Testing and diagnosis

In addition to a complete medical history and physical examination, it would be required to check for osteosarcoma using diagnostic tests such as:8

  • X-rays: Used to produce images of internal tissues, bones, and organs on film.
  • Bone scans: This is a nuclear imaging technique used to evaluate any degenerative and/or arthritic changes in the joints. This is done to scan for any bone diseases and tumours and to determine the cause of bone pain or inflammation.
  • Magnetic resonance imaging (MRI): Used to produce detailed images of organs and structures inside the body. This method is performed to better define a mass captured on X-ray and to look for any nearby spread of tumours.
  • Computed tomography scan (CT or CAT scan): An imaging test that uses X-rays and a computer to make detailed images of the body. A CAT scan shows details of the bones, muscles, fat, and organs.
  • Positron emission tomography (PET) scan: A radioactive-labelled glucose (sugar) is injected into the bloodstream and scanned for use; as tumours use more glucose than normal tissues they can then be tracked down. PET scans can be used to find small tumours that have spread or to check if treatment for a known tumour is working.
  • Complete blood count (CBC): Includes a measurement of the size, number, and maturity of different blood cell types.
  • Other blood tests: Such as blood chemistry
  • Biopsy of the tumour: Tissue samples are removed (using a needle or during surgery) from the body for examination under a microscope to determine if cancer or other abnormal cells are present.

Treatment methods and therapy

Treatment for osteoblastoma and osteosarcoma may include:5, 8

It is important to treat osteoblastoma and osteosarcoma to avoid future complications and have a better prognosis and survival rates. Please refer to your healthcare provider for further details or advice.

Summary

Osteoblastoma and osteosarcoma are rare bone-forming tumours that might not be easily detected from general symptoms. While osteoblastoma is usually benign, osteosarcoma is a more aggressive type of tumour that is malignant. Osteoblastoma tends to affect the lower vertebrae of the spine or long bones of the lower extremities, while osteosarcoma occurs in the long bone around the knee. Both require attention and medical care to manage the severity of the illness and help provide the patient with the best outcome possible. 

References

  1. Wu M, Xu K, Xie Y, Yan F, Deng Z, Lei J, et al. Diagnostic and management options of osteoblastoma in the spine. Med Sci Monit [Internet]. 2019 Feb 20 [cited 2024 Mar 28];25:1362–72. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391855/
  2. Eaton BR, Schwarz R, Vatner R, Yeh B, Claude L, Indelicato DJ, et al. Osteosarcoma. Pediatric Blood & Cancer [Internet]. 2021 May [cited 2024 Mar 28];68(S2):e28352. Available from: https://onlinelibrary.wiley.com/doi/10.1002/pbc.28352
  3. Limaiem F, Byerly DW, Mabrouk A, Singh R. Osteoblastoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Mar 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK536954/
  4. Zoccali C, Novello M, Arrigoni F, Scotto di Uccio A, Attala D, Ferraresi V. Osteoblastoma: when the treatment is not minimally invasive, an overview. Journal of Clinical Medicine [Internet]. 2021 Jan [cited 2024 Mar 28];10(20):4645. Available from: https://www.mdpi.com/2077-0383/10/20/4645 
  5. Philadelphia TCH of. Osteoblastoma [Internet]. 2014 [cited 2024 Mar 28]. Available from: https://www.chop.edu/conditions-diseases/osteoblastoma
  6. Czarnecka AM, Synoradzki K, Firlej W, Bartnik E, Sobczuk P, Fiedorowicz M, et al. Molecular biology of osteosarcoma. Cancers [Internet]. 2020 Aug [cited 2024 Mar 28];12(8):2130. Available from: https://www.mdpi.com/2072-6694/12/8/2130
  7. Prater S, McKeon B. Osteosarcoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 [cited 2024 Mar 28]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK549868/
  8. Osteosarcoma [Internet]. 2020 [cited 2024 Mar 28]. Available from: https://www.hopkinsmedicine.org/health/conditions-and-diseases/sarcoma/osteosarcoma

Get health & wellness advice into your inbox

Your privacy is important to us. Any information you provide to us via this website may be placed by us on servers. If you do not agree to these placements, please do not provide the information.

Best Milk Alternative
[optin-monster-inline slug="yw0fgpzdy6fjeb0bbekx"]
This content is purely informational and isn’t medical guidance. It shouldn’t replace professional medical counsel. Always consult your physician regarding treatment risks and benefits. See our editorial standards for more details.

Get our health newsletter

Get daily health and wellness advice from our medical team.
Your privacy is important to us. Any information you provide to this website may be placed by us on our servers. If you do not agree do not provide the information.

Tatiana Abdul Khalek

PhD, Anglia Ruskin University, UK

I am a PhD student in Biomedical Science at Anglia Ruskin university and work as a quality control (QC) analyst (microbiology/chemistry) at EuroAPI. I have a MSc in Forensic Science from Anglia Ruskin (Cambridge) and I had experience in different roles such as quality lab technician at Fluidic Analytics, Research Assistant/Lab Manager at Cambridge University and Forensic Analyst at the The Research Centre in Topical Drug Delivery and Toxicology, University of Hertfordshire.

My PhD revolves around the use of nanoparticles and their role in cartilage degradation, as well as their potential as drug delivery vehicles for the treatment of diseases such as leukaemia.

my.klarity.health presents all health information in line with our terms and conditions. It is essential to understand that the medical information available on our platform is not intended to substitute the relationship between a patient and their physician or doctor, as well as any medical guidance they offer. Always consult with a healthcare professional before making any decisions based on the information found on our website.
Klarity is a citizen-centric health data management platform that enables citizens to securely access, control and share their own health data. Klarity Health Library aims to provide clear and evidence-based health and wellness related informative articles. 
Email:
Klarity / Managed Self Ltd
Alum House
5 Alum Chine Road
Westbourne Bournemouth BH4 8DT
VAT Number: 362 5758 74
Company Number: 10696687

Phone Number:

 +44 20 3239 9818
arrow-right